<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Walter</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Newman, Stanton</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">MITRE: No Benefit for Continuous Glucose Monitoring Devices</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-20</style></pages><abstract><style  face="normal" font="default" size="100%">The Minimally Invasive Technology Role and Evaluation [MITRE] Study, a randomized controlled trial of continuous glucose monitoring device use, showed them to be of no greater benefit than standard care. This article discusses the report that all groups, including controls, had a sustained reduction of HbA1C.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>